Skip to main content
Clinical Trials/SLCTR/2015/023
SLCTR/2015/023
Recruiting
Phase 2

A randomized controlled, double blinded, clinical trial investigating the effects of Vitamin E Delta-tocotrienol supplementation in Nonalcoholic fatty liver disease

Armed Forces Institute of Pathology, Pakistan0 sitesTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
onalcoholic fatty liver disease (NAFLD)
Sponsor
Armed Forces Institute of Pathology, Pakistan
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Sponsor
Armed Forces Institute of Pathology, Pakistan

Eligibility Criteria

Inclusion Criteria

  • 1\. Patients of both genders aged 20 years and above.
  • 2\. Ultrasound\-proven fatty liver
  • 3\. Fatty Liver Index (FLI) score of equal to or more than 60
  • 4\. Mild to moderate elevation of alanine transaminase (ALT) and aspartate transaminase (AST) i.e. not greater than four times the upper limit of 42 IU/L and 37 IU/L respectively

Exclusion Criteria

  • 1\. Chronic hepatitis B and C
  • 2\. Alcoholic fatty liver disease
  • 3\. Any other acute or chronic illness including cancer
  • 4\. Autoimmune liver disease
  • 5\. Patients receiving other medications including herbal or vitamin supplements

Outcomes

Primary Outcomes

Not specified

Similar Trials